Article
Preclinical efficacy of the Wnt/β-catenin pathway inhibitor BC2059 for the treatment of desmoid tumors.
PloS one - 1 Jan 2022
Braggio Danielle Almeida, Costas C de Faria Fernanda, Koller David, Jin Feng, Zewdu Abeba, Lopez Gonzalo, Batte Kara, Casadei Lucia, Welliver Meng, Horrigan Stephen K, Han Ruolan, Larson Jeffrey L, Strohecker Anne M, Pollock Raphael E
Abstract excerpt
Mutation in the CTNNB1 gene, leading to a deregulation of the WTN/β-catenin pathway, is a common feature of desmoid tumors (DTs). Many β-catenin inhibitors have recently been tested in clinical studies; however, BC2059 (also referred as Tegavivint), a selective inhibitor of nuclear β-catenin that works through binding TBL-1, is the only one being evaluated in a clinical study, specifically for treatment of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.